"Rhino tranq" is no longer a rumor in New York's street drug scene. Medetomidine, a powerful veterinary sedative, has been showing up again and again in illicit fentanyl and heroin, leaving people in unusually deep, long‑lasting sedation and facing a new kind of withdrawal. State and city testing now suggest it is firmly entrenched in the supply, and public‑health officials say it has been linked with dozens of fatal overdoses across 2024 and 2025. Clinicians and harm‑reduction workers are racing to adjust treatment and spread the word as the drug supply changes faster than many testing tools and clinical protocols can keep up.
Wider testing shows rapid spread
A recent Public Health Alerts analysis from NEJM Evidence and the Center for Infectious Disease Research and Policy found that medetomidine appeared in roughly one quarter of opioid samples across New York State between May 2024 and December 2025, with a monthly high of 44.1% in May 2025. The same review attributes 152 overdose deaths in 2024 and 2025 to medetomidine, with the caveat that some investigations are still open and the final count may change. Those numbers represent a sharp rise from the drug’s first detections in mid‑2024, according to CIDRAP.
Where it showed up in New York
State and city labs first spotted medetomidine on May 24, 2024, after a sample sold as heroin produced unexpectedly strong sedative effects and triggered alerts to medical examiners. New York City’s Health Department now says that in 2025, medetomidine appeared in about 32% of samples sold as opioids that were tested through the city’s drug‑checking program. Death records tell an even starker story, with medetomidine listed as a contributing cause in 18 fatal overdoses in 2024 and 134 in 2025. Nearly all of the medetomidine‑positive samples also contained fentanyl, according to the NYC Health Department.
Why clinicians say it's dangerous
Medetomidine is an alpha‑2 adrenoceptor agonist used in veterinary medicine that can cause pronounced bradycardia, low blood pressure and deep, prolonged sedation. Because fentanyl is present in most medetomidine‑positive samples, public‑health guidance stresses that naloxone should still be given to restore breathing, while clinicians should be prepared for the possibility that heavy sedation will not fully reverse and that extra supportive care may be required. Federal officials also describe a complicated withdrawal picture, including severe hypertension, rapid heart rate, relentless vomiting and shifts between agitation and drowsiness that can require intensive care, according to the CDC.
How local agencies are responding
City and state harm‑reduction teams have widened access to drug‑checking, issued clinical advisories and pushed out palm cards and provider guidance to emergency departments and syringe‑service programs. The NYC Health Department’s advisory recommends treating suspected medetomidine withdrawal with standard opioid‑withdrawal strategies plus alpha‑2 agonist therapy, such as clonidine or, in closely monitored settings, dexmedetomidine. It also urges clinicians to contact the Poison Center at 212‑POISONS for unusual or severe cases. At the community level, officials are asking people who use drugs to carry naloxone, avoid using alone when possible and use drug‑checking services wherever they are available, per the NYC Health Department.
What to do if you or someone is exposed
If you suspect medetomidine is involved in an overdose, responders say the basics still come first: start rescue breathing, call 911 and give naloxone to reverse opioid‑related respiratory depression, while keeping in mind that deep sedation may linger. If it is safe, save a small sample of the drug and bring it to a community drug‑checking site so it can be tested and included in local alerts. New York’s harm‑reduction network and state programs can analyze samples and quickly warn others at risk. Clinicians and public‑health teams say that fast testing, clear public warnings and having naloxone on hand remain the most effective short‑term tools for preventing severe outcomes, according to the New York OASAS advisory.
The rise of medetomidine adds a dangerous new twist to an already deadly opioid market and shows how quickly adulterants can force changes in both clinical care and harm‑reduction work. For now, officials say that awareness, easy access to naloxone and rapid drug‑checking are the most practical ways to blunt the damage while researchers and clinicians work to refine treatment protocols.
